Pharmacological treatment of benign prostatic hyperplasia.
Although surgery remains the standard treatment for benign prostatic hyperplasia there has been a rise in the number of available drugs for this condition. The current drug therapies appear to be useful for symptomatic short-term treatment, particularly for those patients unfit or unwilling to undergo surgical intervention. Further evaluation of the long-term effects of these treatments and their role in early disease is required, but drug therapy is likely to play a more important part in the management of this condition in the future.
Pascual
J
J
University Department of Geriatric Medicine, Cardiff Royal Infirmary, Wales.
Woodhouse
K
K
D058891:5-alpha Reductase Inhibitors; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D058891:5-alpha Reductase Inhibitors; D000316:Adrenergic alpha-Agonists; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists